Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Stock Quote Today & Recent News Fortress Biotech Inc. FBIO

Alternate Symbol(s):  FBIOP

Fortress Biotech Inc is a biopharmaceutical company. The firm is involved in the business of acquiring, developing, and commercializing pharmaceutical and biotechnology products. Its product portfolio encompasses Targadox, Exelderm, Ceracade, Luxamend, and Dermasorb. The business activities of the group are functioned through Dermatology Product Sales, and Pharmaceutical and Biotechnology Product Development. It derives the majority of its revenues from Dermatology segment. Its subsidiaries also operate in biotechnology, pharmaceutical, oncology, therapeutics sectors.

The Power Play by The Market Herald
{{currentVideo.videoCaption}}
< Previous Video {{moreVideoText}} Next Video >

Stock Price Chart (NDAQ:FBIO)

Fundamentals Snapshot (NDAQ:FBIO)

Current News (NDAQ:FBIO)

Journey Medical Corporation Reports Second Quarter 2022 Financial Results and Recent Corporate Highlights

GlobeNewswire 1 day ago

Journey Medical Corporation to Announce Second Quarter 2022 Financial Results on August 9, 2022

GlobeNewswire 7 days ago

Mustang Bio Announces First Patient Successfully Treated by Ex Vivo Lentiviral Gene Therapy to Treat RAG1 Severe Combined Immunodeficiency

GlobeNewswire July 27, 2022

Fortress Biotech Appoints David Jin as Chief Financial Officer

GlobeNewswire July 22, 2022

Mustang Bio Announces Orphan Drug Designation Granted to MB-106, a CD20-targeted, Autologous CAR T Cell Therapy for the Treatment of Waldenstrom Macroglobulinemia

GlobeNewswire June 22, 2022

Checkpoint Therapeutics Announces Positive Interim Results from Registration-Enabling Trial of Cosibelimab in Locally Advanced Cutaneous Squamous Cell Carcinoma

GlobeNewswire June 16, 2022

Mustang Bio Announces Updated Interim Results from Follicular Lymphoma Cohort of Ongoing Phase 1/2 Clinical Trial of MB-106, CD20-Targeted CAR T Therapy

GlobeNewswire June 13, 2022

Checkpoint Therapeutics Announces Presentation of Pivotal Trial Results of Cosibelimab at the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting

GlobeNewswire June 6, 2022

Fortress Biotech Announces First Patient Dosed in Phase 1 Clinical Trial Evaluating Dotinurad for the Treatment of Gout in the United States

GlobeNewswire May 31, 2022

Opinion & Analysis (NDAQ:FBIO)

Understanding Fortress Biotech

Streetwise Reports February 6, 2020

Coverage Initiated on 'Biotech Machine'

Streetwise Reports September 5, 2019

Coverage Initiated on Biopharma With 'Low Risk/High Margin Assets'

Streetwise Reports July 6, 2019

2018 Biotech Watchlist: 'no one space is going to dominate'

Streetwise Reports January 11, 2018

Bullboard Posts (NDAQ:FBIO)

3 BIOTECH STOCKS INSIDERS ARE SELLING

3 BIOTECH STOCKS INSIDERS ARE SELLING $VERU $FBIO $SGMO Learn More https://www.aviseanalytics.com/3-biotech-stocks-insiders-are...
AviseAnalytics - August 26, 2021

BIG news -FBIO - Any time fly soon.

Fortress Biotech Prices Brokered Public Sale of Preferred Stocks at $18 Per Share 27 Aug 2020 07:59 ET   07:59 AM EDT, 08...
HugeMoney - August 27, 2020

it's a buy today for me

at $1.76 per share,so glta.
coolfooldumbguy - August 26, 2019

40% stake in mbio

we r extremely under valued at the moment
Tiffany - April 23, 2019

This was unexpected.

Very nice launch upwards.  Maybe another good hit if another product moves forward.
Stevercan - February 3, 2019

Had this stock a long time

What a pile OS while management gets millions of shares of the new companies!
Stevercan - November 13, 2017